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Coccidioidomycosis is a common cause of community-
acquired pneumonia (CAP) in disease-endemic areas. Be-
cause testing rates inﬂ  uence interpretation of reportable-dis-
ease data and quality of CAP patient care, we determined the 
proportion of CAP patients who were tested for Coccidioides 
spp., identiﬁ  ed testing predictors, and determined the propor-
tion of tested patients who had positive coccidioidomycosis 
results. Cohort studies to determine the proportion of ambu-
latory CAP patients who were tested in 2 healthcare systems 
in metropolitan Phoenix found testing rates of 2% and 13%. 
A case-control study identiﬁ  ed signiﬁ  cant predictors of test-
ing to be age >18 years, rash, chest pain, and symptoms for 
>14 days. Serologic testing conﬁ  rmed coccidioidomycosis in 
9 (15%) of 60 tested patients, suggesting that the propor-
tion of CAP caused by coccidioidomycosis was substantial. 
However, because Coccidioides spp. testing among CAP pa-
tients was infrequent, reportable-disease data, which rely on 
positive diagnostic test results, greatly underestimate the true 
disease prevalence.
C
occidioidomycosis (valley fever) is a disease caused 
by Coccidioides spp., dimorphic fungi that thrive in 
the alkaline soil of warm, arid climates (1). Infection may 
occur when conidia in disrupted soil are inhaled. Coccid-
ioidomycosis-endemic areas include the southwestern Unit-
ed States, parts of Mexico, and Central and South America. 
In the United States, these areas include parts of Arizona, 
California, New Mexico, Nevada, Texas, and Utah (1).
The clinical manifestations of coccidioidomycosis 
have been well established (2–4); 1–3 weeks after a person 
inhales the spores, most persons with symptomatic infec-
tion will have a clinical syndrome consistent with commu-
nity-acquired pneumonia (CAP) (3). Serologic testing is 
the most frequently used method for diagnosis of primary 
pulmonary coccidioidomycosis (3,5). For most patients, se-
rologic reactivity ends after a few months unless infection 
is active.
Although 95% of symptomatic pulmonary infections 
are self-limiting and resolve after several weeks or months 
without antifungal therapy, ≈5% progress to asymptomatic 
residua, such as pulmonary nodules or cavities (2). Among 
all recognized infections, extrapulmonary disease involv-
ing the meninges, bones and joints, skin, and soft tissues 
occurs in <5% (2). Risk factors for severe or disseminated 
infection include immunosuppression, diabetes, preexist-
ing cardiopulmonary disease, second- or third-trimester 
pregnancy, and African or Filipino descent (6).
Previous studies suggest that the true prevalence of 
coccicioidomycosis is substantially underestimated (6,7). 
One study, which used rates of skin-test conversion, esti-
mated that clinical illness would develop in ≈30,000 per-
sons per year in southern Arizona (7). Another study found 
that coccidioidomycosis was serologically conﬁ  rmed for 
29% of CAP patients in primary care clinics in Tucson, 
Arizona (8). To understand more about the unmeasured 
prevalence of disease, we evaluated Coccidioides spp.test-
ing practices for ambulatory clinic patients with CAP in 
Maricopa County, which encompasses most of metropoli-
tan Phoenix in Arizona, a state where coccidioidomycosis 
is reportable. Our objectives were to estimate the proportion 
of patients with CAP who were tested for coccidioidomy-
cosis, to determine predictors of testing, and to determine 
the proportion of CAP patients who had coccidioidomyco-
sis. To accomplish our objectives, we performed 3 related 
studies: a data analysis, a retrospective cohort study, and a 
case–control study.
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Methods
Descriptive Epidemiology
To describe the epidemiology of coccidioidomycosis 
in metropolitan Phoenix, we analyzed data from the Na-
tional Electronic Telecommunication System for Surveil-
lance. We calculated county-speciﬁ  c and age group–specif-
ic incidence rates for 1999–2004. Population denominators 
were obtained from the US Census Bureau (http://quick-
facts.census.gov/qfd/index.html).
Retrospective Cohort Studies
To determine the proportions of CAP patients tested 
for  Coccidioides  spp., we performed retrospective cohort 
studies in 2 healthcare systems (systems A and B) in metro-
politan Phoenix. System A served large numbers of patients 
without private insurance, whereas system B was associated 
with an insurance company. System A comprised 13 clinics 
and system B comprised 17 (Table 1). Race and ethnicity 
data were available for patients in system A (19% white, 6% 
black, 69% Hispanic, 4% other) but not system B. 
Administrative databases from both systems were 
screened to identify outpatient visits from January 1, 2003, 
through December 31, 2004, in which patients were as-
signed primary or secondary codes from the International 
Classiﬁ  cation of Diseases, 9th revision (ICD-9), beginning 
with 486 (pneumonia, organism unspeciﬁ  ed). Patient charts 
were selected by simple random sampling for chart review 
to determine whether patients met inclusion criteria. Patients 
were included if their initial visit was as an outpatient, they 
had no history of coccidioidomycosis, and they had CAP as 
deﬁ  ned by the clinician. Patients were excluded if they were 
hospitalized or had been residents of a long-term care facil-
ity within 14 days of symptom onset. Demographic, clinical, 
diagnostic data (including Coccidioides spp. testing), and 
outcomes were extracted from medical records for all subse-
quent visits within 2 months after the initial clinic visit.
Preliminary results, obtained by using Current Proce-
dural Terminology codes for Coccidioides spp. serologic 
testing (86635, 86329, 86331, or 86171), indicated that 
13% of patients in system B were being tested for Coccid-
ioides spp. compared with 1% in system A. Assuming α = 
0.05 and a power of 80%, a sample size of 86 was needed 
for each cohort to show a difference in testing frequency 
between the 2 systems.
Case–Control Study
To determine factors associated with coccidioidomyco-
sis testing (testing predictors) among CAP patients, we con-
ducted a case–control study in system B. We identiﬁ  ed all 
ambulatory patients who had visited system B in 2003 and 
2004 and had an ICD-9 code for “pneumonia, organism un-
speciﬁ  ed” and a Current Procedural Terminology code for 
Coccidioides spp. serologic testing. Patients with CAP were 
deﬁ  ned by the same criteria used in the cohort studies. Case-
patients were deﬁ  ned as CAP patients who had received 
Coccidioides spp. serologic testing, regardless of test result. 
Controls were deﬁ  ned as patients who met the deﬁ  nition 
for CAP but had not received Coccidioides spp. serologic 
testing. A simple random sample of visits was reviewed to 
conﬁ  rm inclusion criteria and to conﬁ  rm Coccidioides spp. 
serologic testing associated with the pneumonia.
Statistical Analysis
All data were entered into Epi Info (Centers for Dis-
ease Control and Prevention [CDC], Atlanta, GA, USA). 
Analysis was performed in Epi Info, SAS version 9.1 (SAS 
Institute, Inc., Cary, NC, USA), and StatXact 6 (Cytel Soft-
ware Corp., Cambridge, MA, USA). Conﬁ  dence intervals 
(CIs) on difference in proportions were determined by as-
suming 2 independent binomial proportions and using an 
exact method. The Kruskal-Wallis test was used to com-
pare continuous variables. Univariate logistic regression 
models related the dependent variable (a clinician ordering 
a test for Coccidioides spp.) to independent variables such 
as age (>18 years vs. <18 years); reported rash; chest pain; 
symptoms >14 days, as well as other demographic or clini-
cal symptom characteristics. A ﬁ  nal multivariable model 
was chosen by using the stepwise selection procedure. 
Independent variables that remained signiﬁ  cant (α<0.05) 
while other signiﬁ  cant variables were controlled for were 
included in the ﬁ  nal model. Exact 95% CIs are reported 
because of low observed cell counts. 
Results
Descriptive Epidemiology
In 2004, Maricopa County had the most reported 
cases of coccidioidomycosis in Arizona (2,704 cases), fol-
lowed by Pima and Pinal Counties (715 and 164 cases, 
respectively). Compared with other counties in Arizona, 
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Table 1. Characteristics of healthcare systems selected for retrospective cohort studies, Maricopa County, Arizona 
Characteristic System A  System B 
Primary care  Yes  Yes 
Subspecialty care  Yes  Yes 
No. clinics  13 17
Associated with hospital  Yes (public)  No
Racial and ethnic minorities  Majority  Data not available 
Insurance Many without insurance  Most privately insured Testing for Coccidioidomycosis among CAP Patients
Maricopa, Pima, and Pinal Counties also had the highest 
incidence rates (77, 77, and 75 cases per 100,000 persons, 
respectively). The incidence rate in Maricopa County has 
increased from 42 per 100,000 persons in 1999 to 77 cases 
per 100,000 persons in 2004. Maricopa County shows a 
seasonal pattern with cases peaking in the winter season 
(Figure), similar to ﬁ  ndings reported elsewhere (9). Coc-
cidioidomycosis was reported in every 5-year age category; 
the incidence rate for coccidioidomycosis was 8/100,000 
for those <5 years of age and increased steadily with each 
age group; incidence for persons 55–64 years of age was the 
highest (166/100,000). Groups of persons >65 years of age 
also had high incidence rates (65–74 years, 161/100,000; 
75–84 years, 147/100,000; >85 years, 153/100,000).
Retrospective Cohort Studies
Participants
In system A, 619 visits for “pneumonia, organism 
unspeciﬁ  ed” were identiﬁ  ed, from which 132 (21%) were 
sampled for chart review. From the 132, 66 (50%) were 
excluded: 11 had no charts available, 21 were miscoded 
or did not have a clinical diagnosis of pneumonia, 30 were 
initially hospitalized, and 4 had been residents of long-term 
care facilities or hospitalized within the 14 days before 
symptom onset. The remaining 66 patients were conﬁ  rmed 
by chart review to have CAP and were included.
In system B, 14,695 visits for “pneumonia, organism 
unspeciﬁ  ed” were identiﬁ  ed, from which 159 (1%) were 
sampled for chart review. From the 159, 72 (46%) were 
excluded: 6 had no charts available, 25 did not have clear 
documentation of pneumonia, 37 were initially hospital-
ized, 1 had been hospitalized within 14 days before symp-
tom onset, and 3 had a history of coccidioidomycosis. The 
remaining 87 patients were therefore included.
Patient Characteristics and Clinical 
Description (Table 2)
Of CAP patients, 11% of those in system A were <18 
years of age compared with 37% in system B (difference 
26%, 95% CI 12%–39%, p<0.01). Patients in system A 
were signiﬁ  cantly more likely than patients in system B to 
have been seen initially in an emergency department (26% 
vs. 6%, difference 20%, 95% CI 7%–33%, p<0.01).
Clinical signs and duration of symptoms before the ini-
tial visit were similar for patients in both systems. In sys-
tems A and B, respectively, cough was the most commonly 
reported symptom (82% and 79%), followed by fever (33% 
and 58%) and dyspnea (27% and 26%). Approximately 
50% of patients in each group had focal ﬁ  ndings on lung 
examination.
In terms of coexisting conditions, 38% of patients in 
system A had diabetes compared with 8% in system B (dif-
ference 30%, 95% CI 16%–43%, p<0.01); diabetes is a 
risk factor for severe pneumonia and for complicated Coc-
cidioides spp. infection (10). Similar proportions of those 
with asthma or chronic obstructive pulmonary disease 
were found in both systems. Few patients had a diagnosis 
of HIV, pregnancy, or organ transplantation, and few were 
receiving immunosuppressive medications.
Chest radiographs were less likely to have been taken 
for patients in system A than for patients in system B (23% 
vs. 83%, difference 60%, 95% CI 47%–72%, p<0.01). Of 
those in both systems who did have chest radiographs taken, 
similar proportions had ﬁ  ndings consistent with pneumonia 
(78% and 81%, respectively). All patients in both systems 
received treatment with antibacterial drugs.
Coccidioides spp. serologic testing was low overall for 
patients in systems A (1/66, 2%, 95% CI 0.04%–8%) and 
B (11/87, 13%, 6%–22%). Patients in system A were sig-
niﬁ  cantly less likely than patients in system B to have had 
Coccidioides spp. serologic testing performed at any point 
during the clinical course of disease (difference 11%, 95% 
CI 3%–20%, p = 0.01). In system B, 7 (64%) of 11 tested 
patients were tested during a follow-up visit rather than at 
the initial visit. Of those 11 patients, 1 (9%) had a reactive 
serologic test result for Coccidioides spp. Median duration 
of symptoms before testing for patients in system B was 27 
days (range 1–99 days); most patients (64%) were tested 
after symptoms had been present for at least 2 weeks.
Patient outcomes were similar. In system A, 2 (3%) were 
known to have been hospitalized for worsening of pneumo-
nia, and no patients were known to have died. In system B, 
6 patients (7%) were hospitalized for worsening pneumonia, 
and 2 died; cause-of-death data were unavailable.
Case–Control Study
Of 14,695 potential CAP-patient visits in system B, we 
randomly selected 60 case-patients (i.e., those with CAP 
who had been tested for Coccidioides spp.) and 76 controls 
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Figure. Coccidioidomycosis cases reported by month, Maricopa 
County, Arizona, 1999–2004.RESEARCH
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Table 2. Demographic and clinical characteristics of patients with community-acquired pneumonia included in retrospective cohort
studies, Maricopa County, Arizona, January 2003–December 2004* 
Patient characteristic 
System A (% or range), 
n = 66 
System B (% or range),  
n = 87 
Absolute difference in 
percentages (95% CI)* 
Evaluated initially in emergency department 17 (26) 5 (6) 20 (7–33)†
Median age, y (range) 54 (6–90) 37 (0–86)
Age <18 y 7 (11) 32 (37) 26 (12–39)†
Male 30 (46) 47 (54) NS
Median no. days of symptoms before 1st visit 8 (1–30) 7 (1–60) NS
Symptoms for >21 d at time of 1st visit 4 (9) 6 (7) NS
Symptoms 
  Fever  22 (33) 50 (58) NS
   Chills 5 (8) 12 (14) NS
   Night sweats 0 4 (5) NS
   Myalgias 2 (3) 3 (3) NS
   Fatigue 4 (6) 4 (5) NS
   Cough 54 (82) 69 (79) NS
   Dyspnea 18 (27) 23 (26) NS
   Chest pain 10 (15) 11 (13) NS
   Wheezing 8 (12) 9 (10) NS
Signs
   Temperature >100.4°F 10 (15) 24 (28) NS
   Tachycardia 8 (12) 11 (13) NS
   Focal lung examination 37 (56) 44 (51) NS
   Hypoxia 0 0 NS
   Rash 0 0 NS
Immunosuppressive medication 2 (3) 1 (1) NS
Coexisting conditions 
   Asthma 10 (15) 23 (26) NS
   Chronic obstructive pulmonary disease 13 (20) 12 (14) NS
   Diabetes mellitus 25 (38) 7 (8) 30 (16–43)†
   HIV infection 0 1 (1) NS
   Pregnancy 1 (2) 0 NS
   Transplant 1 (2) 0 NS
   Malignancy 1 (2) 3 (3) NS
Diagnostic testing, noncoccidioidal 
  Chest radiograph 23 (35) 83 (95) 61 (47–72)†
   Radiographically proven pneumonia  18 (27) 67 (83) 50 (35–63)†
Treatment and outcome 
   Antibacterial drugs 66 (100) 87 (100) NS
 Follow-up  visits 
  None  17  (26)  27  (31)  NS
  1  34  (52)  27  (31)  NS
  2  5  (8)  13  (15)  NS
>3 10 (15)  20 (23)  NS
 Hospital  admissions 2 (3) 6 (7) NS
   Died 0 (0) 2 (2) NS
Coccidioides spp. serologic testing 
   At any visit 1 (2) 11 (13) 11 (3–20)‡
   During follow-up visit  0 4 (5) NS
   Reactive results 0 1 (1) NS
  Median no. days before testing 12 27 (1–99) –
   Symptoms >14 days before testing 0 7 (64) NS
Diagnosis of coccidioidomycosis, any technique  0 1 (1)  NS
CI, confidence interval; NS, not significant. CIs on difference in percentages were performed by using an exact method with 2 independent binomial 
proportions. 
†p<0.01. 
‡p<0.05. Testing for Coccidioidomycosis among CAP Patients
(i.e., those with CAP who had not been tested). According 
to univariate analysis, patients who had chest pain (odds 
ratio [OR] 4.6, 95% CI 1.8–11.8), rash (OR undeﬁ  ned, 95% 
CI 1.2–undeﬁ  ned), or those with symptom duration >14 
days (OR 5.8, 95% CI 2.1–15.7) were signiﬁ  cantly more 
likely to have been tested (Table 3). Additionally, patients 
>18 years of age (OR 5.5, 95% CI 2.1–15.3) and those 
who had diabetes or were receiving an immunosuppressive 
medication (OR 3.6, 95% CI 1.0–16.5) were signiﬁ  cantly 
more likely to have been tested.
The multivariate model identiﬁ  ed the following as be-
ing signiﬁ  cantly more likely to have been tested for coc-
cidioidomycosis: adult patients (adjusted OR 5.3, 95% CI 
1.5–24.0) and those who reported rash (adjusted OR 21.1, 
95% CI 2.2–∞), chest pain (adjusted OR 3.9, 95% CI 1.2–
13.8), or symptoms for >14 days (adjusted OR 4.1, 95% 
CI 1.3–14.2). The Hosmer-Lemeshow goodness-of-ﬁ  t test 
showed no evidence of a lack of ﬁ  t (p = 0.8).
Of the 60 case-patients who were tested for Coccid-
ioides spp., 9 (15%, 95% CI 8%–26%) had positive results. 
Of these 9, 3 had immunoglobulin (Ig) M by enzyme im-
munoassay alone, 3 had IgM and IgG by enzyme immuno-
assay (IgG titers 4, 8, and 8 by complement ﬁ  xation), 1 had 
IgM and IgG by immunodiffusion, 1 had a single high IgG 
titer (128), and another had a rising IgG titer (<2 initial; 16 
at 4 weeks).
Discussion
Our study directly measured serologic testing practices 
for coccidioidomycosis. The proportion of ambulatory pa-
tients with CAP who were tested for Coccidioides spp. was 
low in this coccidioidomycosis-endemic area.
Because incidence rates of CAP in this area of the 
United States are not available, the number of CAP pa-
tients who do not receive serologic testing for Coccidioides 
spp. cannot be estimated. However, if incidence rates are 
comparable to those in other parts of the country (6), the 
number of patients with CAP who are not tested for coc-
cidioidomycosis would be high. If CAP is the result of coc-
cidioidomycosis in as many as 10%–15% of these untested 
patients, then large numbers of patients would remain un-
diagnosed.
According to recently published Infectious Disease 
Society of America (IDSA) guidelines, the beneﬁ  t of anti-
fungal therapy for uncomplicated respiratory Coccidioides 
spp. infection is unknown (6). However, treatment is more 
likely to beneﬁ  t groups at risk for severe or disseminated 
infection (6). Although these groups are especially likely 
to beneﬁ  t from early testing for coccidioidomycosis, other 
beneﬁ  ts of early diagnosis may exist for all patients with 
coccidioidomycosis, regardless of risk for severe disease. 
Such beneﬁ  ts may include avoidance of unnecessary use of 
antibacterial agents, earlier identiﬁ  cation of complications, 
decreased need for further expensive diagnostic studies, 
and reduction of patient anxiety (3).
Reasons that CAP patients may not be tested for Coc-
cidioides spp. are unclear but are likely complex. First, 
professional consensus for optimal testing practices may 
have been lacking. Although guidelines developed by na-
tional professional organizations for the management of 
CAP were available during the study period (11–13), these 
guidelines did not directly address the best strategy for 
Coccidioides spp. serologic testing (11–13). IDSA guide-
lines for the treatment of coccidioidomycosis also did not 
clearly recommend serologic testing for patients with CAP 
(6,14). The most recent IDSA/American Thoracic Society 
guidelines for CAP, published after the study period, now 
recommend evaluating travel history or exposure to dis-
ease-endemic area during the initial assessment rather than 
waiting for a failed response to therapy (15); these guide-
lines may lead to increased testing for coccidioidal CAP. 
Second, physicians may be unaware of the beneﬁ  ts of early 
testing or the possible high prevalence of coccidioidomy-
cosis in those with CAP in Arizona and therefore may not 
understand the utility of testing. Regardless of the reasons, 
the lack of testing in the presence of widespread disease 
hampers epidemiologic understanding of this disease and 
subsequently may affect public health decisions related to 
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Table 3. Characteristics of patients with community-acquired pneumonia (CAP) who were tested for coccidioidomycosis, Maricopa 
County, Arizona, January 2003–December 2004* 
Characteristic
Case-patients, no. (%), 
n = 60 
Controls, no. (%), 
n = 76  Odds ratio (95% CI) 
Adjusted odds ratio† 
(95% CI) 
Age >18 y 53 (88) 44 (58) 5.5 (2.1–15.3)‡ 5.3 (1.5–24.0)
Male 28 (55) 40 (53) 0.9 (0.5–1.9) NS
Chest pain 19 (32) 7 (9) 4.6 (1.8–11.8)‡ 3.9 (1.2–13.8)
Rash 5 (8) 0 Undefined (1.2–Undefined)‡ 21.1§ (2.2–undefined)
Diabetes mellitus or 
immunosuppressive condition
10 (17) 4 (5) 3.6 (1.0–16.5)‡ NS
Symptoms >14 d 20 (33) 6 (8) 5.8 (2.1–15.7)‡ 4.1 (1.3–14.2)
*CI, confidence interval; NS, not significant. Case-patients were patients who had CAP and had received Coccidioides spp. serologic testing, regardless 
of test result; controls were patients who had CAP but had not received Coccidioides spp. serologic testing. 
†Adjusted odds ratios and exact 95%CI from a multivariable logistic regression model. 
‡Significant (p<0.05) according to univariate analysis. 
§Median unbiased estimate of the adjusted odds ratio. RESEARCH
resource allocation to control disease, educate physicians, 
and develop a vaccine.
Our data also illustrate the marked differences in pro-
cess of care for ambulatory patients with CAP in different 
health systems. Patients in the uninsured population, system 
A, were less likely to be tested than patients in the primarily 
insured population, system B. This disparity is evidenced 
by the higher proportion of CAP patients in the insured sys-
tem who received chest radiography in addition to serologic 
testing. Public health ofﬁ  cials may be able to address these 
disparities by providing general recommendations for diag-
nostic testing of patients with CAP in coccidioidomycosis-
endemic areas; process-of-care measures such as chest radi-
ography and Coccidioides spp. serologic testing may help 
determine effectiveness of such interventions.
Of the tested CAP patients in system B, 15% had se-
rologic evidence of recent Coccidioides spp. infection; this 
proportion is much lower than that (29%) found in a re-
cently reported study (8). Several differences may explain 
this discrepancy. First, our study population was located 
in a different area of Arizona. Second, our deﬁ  nition of 
CAP differed from the deﬁ  nition used in the other study 
and is likely more representative of actual CAP found in 
outpatient practices (8). However, our proportion may 
overestimate the true proportion of CAP caused by coccid-
ioidomycosis because testing in our cohort was subject to a 
decision made by the treating physician. Nevertheless, the 
high proportion could signify that a large number of pul-
monary coccidioidomycosis diagnoses are likely missed in 
Maricopa County alone and that the overall extent of pul-
monary coccidioidomycosis is higher than that indicated by 
reportable disease data. Further studies are needed to better 
quantify the extent of disease.
Our study has several limitations. First, in contrast to 
deﬁ  nitions used in many studies, our deﬁ  nition of CAP in-
cluded patients whose diagnosis was made by a clinician 
without a chest radiograph or with a negative chest radio-
graph. However, although some patients may not have tru-
ly had CAP, our deﬁ  nition reﬂ  ects what clinicians actually 
believed they were treating, which is clinically relevant to 
whether a diagnostic test is ordered. Second, although the 
study populations were geographically dispersed through-
out metropolitan Phoenix and included varied population 
segments, they may not be generalizable to populations in 
health systems in other areas of Arizona. Third, at system 
B, controls were inadvertently oversampled during 2003, so 
we were unable to include visit year in our analysis. How-
ever, it is unlikely that the biased selection based on year 
led to substantial bias for other variables such as age, sex, 
clinic location, signs, symptoms, coexisting medical condi-
tions, or testing. Fourth, data on socioeconomic status were 
not available for either system, and race or ethnicity data 
were not available from system B. Fifth, because our study 
evaluated ambulatory rather than hospitalized patients with 
CAP, our conclusions cannot be generalized to the hospital, 
where testing practices are likely to differ.
Our study shows that testing for Coccidioides spp. 
among ambulatory patients with CAP is infrequent in met-
ropolitan Phoenix. Providers in metropolitan Phoenix and 
other coccidioidomycosis-endemic areas should consider 
testing patients with CAP for coccidioidomycosis. Further 
epidemiologic studies are needed to better determine the 
true extent of pulmonary coccidioidomycosis.
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